S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
NASDAQ:PRTA

Prothena - PRTA Stock Forecast, Price & News

$31.30
-1.71 (-5.18%)
(As of 08/9/2022 10:10 AM ET)
Add
Compare
Today's Range
$31.30
$33.08
50-Day Range
$22.73
$33.11
52-Week Range
$21.06
$79.75
Volume
1,147 shs
Average Volume
265,029 shs
Market Capitalization
$1.47 billion
P/E Ratio
25.66
Dividend Yield
N/A
Price Target
$70.33

Prothena MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.1% Upside
$70.33 Price Target
Short Interest
Bearish
6.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.10mentions of Prothena in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.53) to ($2.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

321st out of 1,098 stocks

Pharmaceutical Preparations Industry

136th out of 536 stocks

PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Prothena Trading Down 0.3 %

NASDAQ:PRTA opened at $33.01 on Tuesday. Prothena has a 1 year low of $21.06 and a 1 year high of $79.75. The firm's fifty day simple moving average is $28.59 and its 200 day simple moving average is $31.51. The firm has a market capitalization of $1.55 billion, a PE ratio of 27.06 and a beta of 1.31.

Analysts Set New Price Targets

Separately, JMP Securities dropped their price target on shares of Prothena from $77.00 to $50.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 25th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $70.33.

Insider Activity at Prothena

In related news, Director Shane Cooke sold 15,000 shares of the firm's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $32.90, for a total value of $493,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Prothena news, Director Shane Cooke sold 15,000 shares of the firm's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $32.90, for a total value of $493,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Gene G. Kinney sold 21,506 shares of the firm's stock in a transaction on Friday, August 5th. The stock was sold at an average price of $32.83, for a total transaction of $706,041.98. Following the completion of the sale, the chief executive officer now owns 12,793 shares in the company, valued at $419,994.19. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,322 shares of company stock worth $3,180,399. 31.20% of the stock is owned by insiders.

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

Prothena (PRTA) Set to Announce Quarterly Earnings on Monday
Prothena Co. plc (NASDAQ:PRTA) CFO Sells $238,266.00 in Stock
Prothena (NASDAQ:PRTA) Shares Gap Up to $31.35
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.33
High Stock Price Forecast
$103.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+124.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$66.97 million
Pretax Margin
32.76%

Debt

Sales & Book Value

Annual Sales
$200.58 million
Cash Flow
$1.50 per share
Book Value
$10.00 per share

Miscellaneous

Free Float
32,203,000
Market Cap
$1.47 billion
Optionable
Optionable
Beta
1.31














PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2022?

5 equities research analysts have issued 12-month price targets for Prothena's shares. Their PRTA share price forecasts range from $14.00 to $103.00. On average, they anticipate the company's stock price to reach $70.33 in the next year. This suggests a possible upside of 113.1% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How has Prothena's stock performed in 2022?

Prothena's stock was trading at $49.40 at the beginning of the year. Since then, PRTA shares have decreased by 33.2% and is now trading at $33.01.
View the best growth stocks for 2022 here
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) posted its earnings results on Thursday, November, 4th. The biotechnology company reported $2.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.25 by $0.12. The biotechnology company earned $139.17 million during the quarter, compared to the consensus estimate of $140.08 million. Prothena had a trailing twelve-month return on equity of 16.02% and a net margin of 33.45%. During the same quarter last year, the business earned ($0.77) earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SG Americas Securities LLC (0.33%), Pinnacle Associates Ltd. (0.31%), Handelsbanken Fonder AB (0.27%), TD Asset Management Inc. (0.24%), Victory Capital Management Inc. (0.04%) and Strs Ohio (0.04%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $33.01.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $1.55 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or $1.22 on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 82 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.